עם ישראל חי
Israel delivery includedPriced BAC Water and NAD+ in ILS · estimated 1–2 business-day delivery (Sunday–Thursday)Choose a product →
Laboratory research materials only · Research purchaser verification required
My account ↗
Israel · ILS checkout for priced BAC Water and NAD+ sizes only · other materials by inquiry

BPC-157 research: human studies, animal models and evidence table

BPC-157 is a 15-amino-acid research peptide. Experimental interest in tissue responses does not establish that a commercially sourced vial safely treats injuries in people. Mechanistic plausibility, clinical effectiveness and product quality are separate questions.

An October 2026 systematic review searched human studies through June 1, 2026. It included three studies totaling 30 participants across different indications, judged their methods poor and the certainty of evidence very low. This is not a controlled demonstration of injury recovery or long-term safety.

BPC-157 versus a blend: compare composition, not nicknames

BPC-157 versus a blend: compare composition, not nicknames
Material describedRequired identity checkDocumentation boundary
BPC-157 aloneFull compound identity, chemical form and amountMatch the report to this material and lot
BPC-157 + TB-500Identity and amount of each component, not just the totalA single-component report does not automatically cover the blend
Wolverine / וולבריןCheck the actual composition behind the nicknameThe nickname does not establish a ratio, result or medical benefit

Common questions

What is BPC-157?

BPC-157 is a synthetic peptide of 15 amino acids. Search spellings such as BPC 157, BPC-157 and בי פי סי 157 refer to the topic, not proof that separately sourced materials are identical.

Is an online BPC-157 review clinical evidence?

A supplier page, testimonial or forum discussion is not a controlled human study. Identify the original study, its population, design and limitations. The small human evidence base does not establish a self-treatment protocol.

Poolton et al., 2026: human-evidence systematic review

Selected primary studies—not a systematic census

This ledger separates published observations from our interpretation. Human pilot reports cannot be combined with rat or cell results into a human success rate. Selection covers the named primary reports and representative tendon mechanisms; it is not a preregistered systematic review. Dates below are publication dates, not necessarily when the experiments ran.

BPC-157 evidence by experimental model
Study / dateModel / designReported findingWhat remains unproven
Lee & Padgett · July 2021Human; retrospective knee-pain charts, 17 records / 16 telephone respondents; 12 BPC-only, 4 BPC + TB411/12 BPC-only and 3/4 combination respondents reported improvement.No randomized control, validated functional scale or follow-up imaging; recall and selection bias. TB4 in this paper does not establish equivalence to a retail TB-500 blend.
Lee, Walker & Ayadi · October 2024Human; uncontrolled pilot, 12 women with interstitial cystitisThe authors reported symptom improvement after bladder-directed treatment.Small single-arm report; cannot separate treatment from placebo, natural variation or other care. Not a tendon-healing trial.
Lee & Burgess · September 2025Human; short intravenous safety pilot, 2 adultsNo adverse effects or clinically important changes were reported in the short observation period.Two participants cannot establish uncommon harms, repeated-use safety, efficacy or human pharmacokinetics. Do not infer a measured half-life from this report.
Starešinić et al. · 2003Animal and laboratory; surgically transected rat Achilles tendons and cultured tendon cellsImproved mechanical and tissue-repair measures were reported over early follow-up.A surgically created rat injury is not a clinical outcome in people; independent replication and human controlled trials remain necessary.
Chang et al. · March 2011Laboratory; rat tendon explants and fibroblastsGreater outgrowth, survival under stress and migration were reported; proliferation was not directly increased in the MTT assay.Cell behavior is a mechanistic observation, not proof of pain relief, tissue regeneration or a safe human exposure.
Chang et al. · November 2014Laboratory; rat Achilles-tendon fibroblastsGrowth-hormone receptor expression and response to growth hormone were investigated.Receptor expression in cultured rat cells does not demonstrate muscle gain or clinical recovery in people.

Why different sources count human studies differently

A July 2026 FDA briefing also lists older PL14736 clinical meeting abstracts: a Phase 1 program reported in 2002/2003 and a 2005 ulcerative-colitis trial. Two abstracts from one program are not two independent trials. Abstract-only records lack the detail of full publications; we do not present them as fully appraised randomized-trial evidence.

ClinicalTrials.gov NCT02637284 was rechecked October 22, 2026. Its study status remained unknown and its last posted record update was December 22, 2015. The results tab distinguishes submitted information from publicly posted results: a May 23, 2016 submission cycle is marked canceled, with no cancellation date supplied. This is not a confirmed cancellation of the study itself, a published outcome or evidence that a review is currently pending. Planned enrollment is not a confirmed completed sample. The registry gap and older abstracts also make “only three human studies ever” misleading; a review’s included studies depend on its criteria.

BPC-157 capsules, study tablets and vials: what is being compared?

The PCO-02 registry describes a randomized, placebo-controlled Phase 1 protocol using oral study tablets in healthy volunteers, with estimated enrollment of 42. It specifies safety and pharmacokinetic questions, not demonstrated injury healing. The study formulation is not automatically equivalent to a commercial capsule, salt form, laboratory vial or blend.

Formulation and evidence are separate questions
Material / formulationWhat to verifyWhat the name alone cannot establish
PCO-02 study tabletsExact protocol and publicly available results, if postedA registered protocol is not a completed efficacy result.
Commercial capsules or an arginate labelExact chemical form, complete formulation and evidence for that productThe PCO-02 record does not validate another finished product.
Single-compound laboratory vialIdentity, batch, counterion, water and measured peptide contentHPLC area purity is not net content, sterility or clinical suitability.
BPC-157 + TB-500 / Wolverine blendIdentity and content of each component; actual study materialsA result for one component does not demonstrate blend synergy.

For analytical comparison, identify the material before comparing amounts or purity percentages. The linked quality-testing and COA guides explain why identity, HPLC area purity and measured content answer different questions. None of these measurements alone establishes safety or effectiveness in people.

From mechanism to a useful research question

A credible next experiment specifies peptide identity/form, independent batch characterization, controls, blinded assessment and a prespecified endpoint. An improvement in a cell-migration assay does not establish repaired cartilage, muscle gain or a safe clinical regimen. BPC-157, TB4, TB-500 and a mixed “Wolverine” vial are not interchangeable study materials.

Primary sources and verification records

Illustrative laboratory vials forming the Locked Aminos wordmark
Illustration only, not evidence of a tested batch.

A claim-reading framework

When a supplier cites a study, locate the original paper and identify the model: cells, animals or people. Record the intervention, control, outcome and duration. A change in a laboratory marker is not the same endpoint as functional recovery from a human injury. Look for replication and limitations rather than counting how many papers mention the name.

What remains unresolved

Human safety and effectiveness cannot be inferred from preclinical observations. FDA materials describe concerns about characterization and peptide-related impurities for BPC-157. This is a reason to scrutinize evidence, not a basis for a dosing recommendation. A research label does not resolve those concerns or establish authorization for medical use.

Single compounds and blends are different materials

A BPC-157 vial and a BPC-157 + TB-500 blend do not have the same composition. A blend nickname such as Wolverine does not specify each component amount or chemical form. Verify the actual label, source record and batch report. A certificate for one component or a different blend cannot simply be reused for the combination.

A useful procurement question

Instead of asking which vial is best for recovery, a laboratory can specify the exact substance, amount, analytical requirements and intended in-vitro work. Request any missing batch information before procurement. For injury or recovery advice, consult an appropriately qualified healthcare professional rather than using this catalog to choose a treatment.

Sources and review scope

Sources explain terminology and evidence limits. They are not commercial endorsements or approvals of catalog products. Check the original source for updates.

Catalog identity and documentation

These links identify laboratory materials, not treatments or clinical-trial products.